Abstract
Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88–98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC.
Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC.
Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field.
Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.
Keywords: DNA methylation, epigenetics, epigenetic therapy, histone modifications, medullary thyroid cancer, microRNA.
Recent Patents on Anti-Cancer Drug Discovery
Title:Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Volume: 11 Issue: 3
Author(s): Giovanni Vitale, Alessandra Dicitore, Erika Messina, Concetta Sciammarella, Antongiulio Faggiano and Annamaria Colao
Affiliation:
Keywords: DNA methylation, epigenetics, epigenetic therapy, histone modifications, medullary thyroid cancer, microRNA.
Abstract: Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88–98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC.
Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC.
Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field.
Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.
Export Options
About this article
Cite this article as:
Vitale Giovanni, Dicitore Alessandra, Messina Erika, Sciammarella Concetta, Faggiano Antongiulio and Colao Annamaria, Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (3) . https://dx.doi.org/10.2174/1574892811666160614115356
DOI https://dx.doi.org/10.2174/1574892811666160614115356 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronotherapeutic Drug Delivery Systems - An Approach to Circadian Rhythms Diseases
Current Drug Delivery A Review of Diagnostic Reference Levels in Computed Tomography
Current Medical Imaging Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery Radiolabeled Nucleoside Analogues for PET Imaging of HSV1-tk Gene Expression
Current Topics in Medicinal Chemistry The ARRONAX Project
Current Radiopharmaceuticals Quinoline as a Privileged Scaffold in Cancer Drug Discovery
Current Medicinal Chemistry Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Structural Characterization of Carbohydrates by Fourier Transform Tandem Mass Spectrometry
Current Proteomics Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Differential Proteomic Identification and Bioinformatics Analysis of Femoral Neck in Elderly Female Patients with Hyperuricaemia
Current Proteomics Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer
Current Genomics Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors
Current Medicinal Chemistry Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Radioiodine Treatment of Differentiated Thyroid Carcinoma: The Experience at Seoul National University Hospital
Current Medical Imaging Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets